Results 181 to 190 of about 65,998 (238)

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson   +5 more
wiley   +1 more source

Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Patel R, Post-Zwicker L, Kaur V.
europepmc   +1 more source

ZC3H13‐mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti‐PD‐1 response in HNSCC

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ZC3H13 promotes HNSCC progression and anti‐PD‐1 resistance by enhancing IGF2BP1‐mediated stabilization of CCND1 mRNA in an m6A‐dependent manner. Targeting ZC3H13 suppresses oral tumorigenesis and improves response to PD‐1 blockade. Abstract Background Resistance to immune checkpoint blockade substantially limits its clinical efficacy in head and neck ...
Wenqing Chen, Yun Li, Shuang Chen, Caihua Zhang, Zhi Liu, Kai Sun, Yingyi Li, Chunlong Yang, Wenbin Lei, Kang Li   +9 more
wiley   +1 more source

Efficacy and Safety of Low-Dose Versus Standard-Dose Immunotherapy in Advanced Solid Tumours: A Retrospective Real-World Study From a Resource-Constrained Setting. [PDF]

Cureus
Gupta A, Singhvi J, Lakshmi Narayanan A, Zaidi S, Shekhawat S.   +4 more
europepmc   +1 more source

The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Hypoxia, oncogenic signaling, transcriptional and epigenetic remodeling, and H. pylori–microbiota interactions drive the Warburg effect in gastric cancer. Enhanced glycolysis and lactate export support biosynthesis, remodel the tumor microenvironment, promote stromal activation and immune suppression, and reveal actionable biomarkers and therapeutic ...
Guanmo Liu, Pan Li, Zizhuo Li, Jie Li, Chenggang Zhang, Yihua Wang, Weiming Kang, Xin Ye   +7 more
wiley   +1 more source

Analysis of Treatment Patterns for Mucosal Melanoma Using Real-World Data in the SEER-Medicare-Linked Database. [PDF]

Cancer Med
Zakeri M, Wagner S, Zhu X, Baser O.
europepmc   +1 more source

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 759-761, September 2026.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

The Real‐World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Melanoma can be effectively treated with immune checkpoint inhibitors (ICIs), but information regarding the risks of treatment‐related adverse events (trAEs), immune‐related adverse events (irAEs), and real‐world adverse events (AEs) is scarce.
Yiwei Chen, Xueyan Liang, Xiaoyu Chen, Yan Li   +3 more
wiley   +1 more source

Combined Nivolumab and Ipilimumab Therapy Promotes Immune-Mediated Cardiomyocyte Apoptosis Through TLR4-Myd88-NF-<i>Κ</i>b-Driven Activation of the NLRP3 Inflammasome. [PDF]

Hum Mutat
Gao M, Liu X, Wu L, Jiang Y, Yu J, Zhang Y.   +5 more
europepmc   +1 more source

Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

International Journal of Cancer, Volume 159, Issue 3, Page 683-698, 1 August 2026.
What's New? Although patients with melanoma brain metastases (MBM) may benefit from treatment with immune checkpoint inhibitors (ICIs), which are known to improve survival in advanced melanoma, MBM patients have often been excluded from trials evaluating ICIs.
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, Peter Mohr, Thomas Sickmann, Pia Dücker, Christoffer Gebhardt, Sebastian Haferkamp, Katharina C. Kähler, Friedegund Meier, Claudia Pföhler, Anca Sindrilaru, Patrick Terheyden, Imke von Wasielewski, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Dirk Schadendorf   +18 more
wiley   +1 more source